stimOS GmbH

**stimOS GmbH** is a German-based health care startup that was founded in 2015. The company is dedicated to developing innovative technologies and procedures for refining, functionalizing, and activating implant materials. Their flagship product, spineFuseMBT implants, is designed for spinal fusion surgery. The company's patented surface functionalization technology, MBTosseo, has shown promising results in terms of biocompatibility, infection prevention, healthy bone preservation, and stimulating new bone formation. The most recent development for stimOS GmbH is its Series A investment, which took place on 04 August 2020. The investors involved in this round were **Dietmar Schaffarczyk**, **HTGF | High-Tech Gruenderfonds**, **WEFA GmbH**, and **MBG Baden Wuerttemberg**. The technology developed by stimOS GmbH has been validated by comparative data from the Universities of Constance, Zurich, and Charité Berlin, demonstrating superior results for all MBT surface treatments compared to currently available implant materials. This underscores the potential for significant impact and market disruption within the health care industry. With its strong focus on technological innovation and a reputable network of investors, stimOS GmbH is well-positioned to make a substantial mark in the field of implant materials and surgeries.